MDS

A cancer survivor described the agony of making a life-or-death decision.

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

A phase 2a trial administered the novel drug HT-6184 to its first patient with lower-risk myelodysplastic syndromes.

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

The FDA recently approved Tibsovo for relapsed/refractory MDS with an IDH1 mutation, a treatment option for a disease subset with no options before this approval.

My visits to the local cancer center were very impactful as a cancer survivor, and I consider that staff a part of my family.

From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.

The Food and Drug Administration approved Tibsovo for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation.

COVID is unpredictable and scary, much like cancer.

Trust me, I made the mistake of blaming every symptom on my cancer.

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert.

Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Here’s a look back at blood cancer approvals from the summer of 2023.

The Food and Drug Administration approved Reblozyl to treat low red blood cell count in patients with very low- to intermediate-risk myelodysplastic syndrome.

The Food and Drug Administration granted a priority review to Tibsovo for the treatment of patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome.

Patients with myelodysplastic syndrome should seek an expert opinion on their disease to ensure an accurate diagnosis and proper treatment plan.

I was devastated when I had to stop working due to my cancer diagnosis. However, I eventually found a new line of work that I'm grateful for.

Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too.

The bonds that you make with your doctors can last a lifetime, and I’m so glad to call many of them a friend.

Reblozyl treatment in patients with anemia from lower-risk myelodysplastic syndromes achieved a greater independence from red blood cell transfusions compared with treatment with epoetin alfa.

Patients with lower risk myelodysplastic syndrome may now receive imetelstat — despite it not being FDA-approved.

I experienced unexpected rewards of decluttering.

Cancer taught me not to worry about the little things.